The method of embodiment 51, wherein the composition comprises between about 0.01% to about 20% by weight of the povidone, about 0.01% to about 15% by weight of the povidone, about 0.01% to about 10% by weight of the povidone, about 0.01% to about 7% by weight of the povidone, about 0.01% to about 5% by weight of the povidone, about 0.01% to about 3% by weight of the povidone, about 0.01% to about 2% by weight of the povidone, or about 0.01% to about 1% by weight of the povidone
and inhibiting skin and visceral fibrosis in SSc
[DOI] [PubMed] [Google Scholar] 12.Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT
A.ChaudhuryN
Pharmacokinetics and pharmacodynamics of afamelanotide, a melanocortin 1 receptor agonist, in humans
Mediterranean diet as a tool to combat inflammation and chronic diseases